Copyright
©The Author(s) 2022.
World J Hepatol. Jun 27, 2022; 14(6): 1053-1073
Published online Jun 27, 2022. doi: 10.4254/wjh.v14.i6.1053
Published online Jun 27, 2022. doi: 10.4254/wjh.v14.i6.1053
Treatment | No cirrhosis | Compensated cirrhosis | Decompensated cirrhosis | ||
Naïve HCV infected patient | Previously treated patients | Naïve HCV infected patients | Previously treated patients | ||
Sofosbuvir (400 mg)/Velpatasvir (100 mg) | 12 wk | Sofosbuvir (400 mg)/Velpatasvir (100 mg)/Voxilapevir (100 mg), 12 wk, for all genotypes. ALTERNATIVE: Glecaprevir (300 mg)/Pibrentasvir (120 mg), but not recommended for genotype 3 with Sofosbuvir/NS5A inhibitor | For genotypes 1, 2, 4, 5, and 6 & genotype 3 with NS5A-RAS Y93H negative, 12 wk, but not recommended for genotype 3 with NS5A-RAS Y93H positivity | Sofosbuvir (400 mg)/Velpatasvir (100 mg)/Voxilapevir (100 mg), 12 wk, for genotypes 1, 2, 4, 5, and 6; for genotype 3, 12 wk in addition to weight-based Ribavirin. ALTERNATIVE: Glecaprevir (300 mg)/Pibrentasvir (120 mg), but not recommended for genotype 3 with Sofosbuvir/NS5A inhibitor | Patients with HCV infection who have decompensated cirrhosis, i.e., Child-Pugh class B or class C, should be referred to a medical practitioner with expertise in that condition, ideally in a liver transplant center |
Glecaprevir (300 mg)/Pibrentasvir (120 mg) | 8 wk | 16 wk in addition to Sofosbuvir (400 mg) + weight-based Ribavirin ALTERNATIVE: 12 wk of Sofosbuvir (400 mg)/Velpatasvir (100 mg)/Voxilapevir (100 mg) | 8 wk | 16 wk in addition to Sofosbuvir (400 mg) + weight-based Ribavirin. ALTERNATIVE: 12 wk of Sofosbuvir (400 mg)/Velpatasvir (100 mg)/Voxilapevir (100 mg) in addition to weight-based Ribavirin | |
Elbasvir (50 mg)/Grazoprevir (100 mg) | 12 wk for genotype 1b | 12 wk Sofosbuvir (400 mg)/Velpatasvir (100 mg)/Voxilapevir (100 mg). However, Glecaprevir/Pibrentasvir for 16 wk is not recommended as an alternative for this group of patients | 12 wk for genotype 1B | NA |
- Citation: Salama II, Raslan HM, Abdel-Latif GA, Salama SI, Sami SM, Shaaban FA, Abdelmohsen AM, Fouad WA. Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection. World J Hepatol 2022; 14(6): 1053-1073
- URL: https://www.wjgnet.com/1948-5182/full/v14/i6/1053.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i6.1053